T. Cuisset, C. Frere, and J. Quilici, Predictive Values of Post-Treatment Adenosine Diphosphate???Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients, The American Journal of Cardiology, vol.104, issue.8, pp.1078-1082, 2009.
DOI : 10.1016/j.amjcard.2009.06.007

L. Wallentin, R. C. Becker, and A. Budaj, Ticagrelor versus clopidogrel in patients with acute coronary syndromesN, Engl J Med, vol.36, pp.1045-1057, 2009.

T. Cuisset, P. Deharo, and J. Quilici, Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study, European Heart Journal, vol.35, issue.41, pp.3070-3078, 2017.
DOI : 10.1093/eurheartj/ehu161

A. J. Kirtane, P. B. Parikh, and T. D. Stuckey, Is There an Ideal Level of Platelet P2Y 12 -Receptor Inhibition in Patients??Undergoing Percutaneous Coronary Intervention?, JACC: Cardiovascular Interventions, vol.8, issue.15, pp.1978-1987, 2015.
DOI : 10.1016/j.jcin.2015.08.032

G. Parodi, R. Marcucci, and R. Valenti, High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCIJAMA, pp.1215-1223, 2011.

G. W. Stone, B. Witzenbichler, and G. Weisz, ADAPT-DES InvestigatorsPlatelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyLancet, pp.382-614, 2013.

U. S. Tantry, L. Bonello, and D. Aradi, Working Group on On-Treatment Platelet ReactivityConsensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleedingJ Am Coll Cardiol, pp.62-2261, 2013.

T. Cuisset, C. Grosdidier, and A. D. Loundou, Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine, al. Bleeding and stent thrombosis on P2Y12- inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J, pp.854-863, 1999.
DOI : 10.1016/j.jcin.2013.04.009

L. Bonello, J. Mancini, and M. Pansieri, Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel, Journal of Thrombosis and Haemostasis, vol.59, issue.10, pp.1999-2005, 2012.
DOI : 10.1016/j.jacc.2012.02.026

M. J. Price, P. B. Berger, and P. S. Teirstein, GRAVITAS InvestigatorsStandard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialJAMAA randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI, Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) studyJ Am Coll Cardiol, pp.1097-1105, 2011.

J. P. Collet, T. Cuisset, and G. Rangé, ANTARCTIC investigatorsPlatelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trialLancet, ARCTIC InvestigatorsBedside monitoring to adjust antiplatelet therapy for coronary stentingN Engl J Med, vol.367, pp.2100-2109, 2012.

M. Roffi, C. Patrono, and J. P. Collet, Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)Eur Heart J, pp.37-267, 2016.

C. K. Naber, P. Urban, and P. J. Ong, LEADERS FREE InvestigatorsBiolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-studyEur, Heart J, pp.38-961, 2017.

P. A. Gurbel, K. P. Bliden, and K. Butler, Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study, Circulation, vol.121, issue.10, pp.1188-1199, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.919456

M. Kerneis, J. Silvain, and J. Abtan, Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel, JACC: Cardiovascular Interventions, vol.6, issue.2, pp.158-165, 2013.
DOI : 10.1016/j.jcin.2012.09.012

P. Deharo, C. Pons, and M. Pankert, Effectiveness of switching 'hyper responders' from prasugrel to clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH studyInt CAPITAL InvestigatorsA randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS StudyThromb Haemost, J Cardiol, vol.168, pp.5004-5005, 2013.

T. Palmerini, U. Benedetto, and G. Biondi-zoccai, Long-Term Safety of Drug-Eluting and??Bare-Metal Stents, Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) trialThromb Haemost, pp.2496-2507, 2015.
DOI : 10.1016/j.jacc.2015.04.017